Roche’s Vabysmo showed extended durability, continued
More than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo ...
Read moreMore than 90% of patients had absence of DME after four years in a pre-specified exploratory endpointPeople treated with Vabysmo ...
Read moreVabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can ...
Read morePositive recommendation is based on two Phase III studies. In addition to robust retinal drying with Vabysmo, these data show ...
Read moreIf approved, PiaSky will be the first monthly subcutaneous (SC) treatment for paroxysmal nocturnal haemoglobinuria (PNH) in the EU Additionally, ...
Read moreOCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) ...
Read moreThe study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people ...
Read moreAfter five years of treatment, 91% of children were alive — without treatment, children with Type 1 SMA would not ...
Read moreColumvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse ...
Read moreSubcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by ...
Read moreInavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.